A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis
Status:
Completed
Trial end date:
2017-12-14
Target enrollment:
Participant gender:
Summary
This trial will be a double-blind, multi-center, randomized, placebo controlled study to
evaluate the safety, tolerability, and efficacy of SAN021 study drug when administered for up
to 42 days to adults between the ages of 18 to 65 years who have a clinical diagnosis of
mild-to-moderate plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Santalis Pharmaceuticals, Inc.
Collaborators:
ClinDatrix, Inc. Clinical Trials of Texas, Inc Clinical Trials of Texas, Inc. Derm Research, PLLC Dermatology Research Center of San Antonio DermResearch, Inc Progressive Clinical Research